» Articles » PMID: 33819304

Clinical Characteristics of COVID-19 Patients with Clinically Diagnosed Bacterial Co-infection: A Multi-center Study

Overview
Journal PLoS One
Date 2021 Apr 5
PMID 33819304
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To understand the clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection (CDBC), and therefore contributing to their early identification and prognosis estimation.

Method: 905 COVID-19 patients from 7 different centers were enrolled. The demography data, clinical manifestations, laboratory results, and treatments were collected accordingly for further analyses.

Results: Around 9.5% of the enrolled COVID-19 patients were diagnosed with CDBC. Older patients or patients with cardiovascular comorbidities have increased CDBC probability. Increased body temperature, longer fever duration, anhelation, gastrointestinal symptoms, illness severity, intensive care unit attending, ventilation treatment, glucocorticoid therapy, longer hospitalization time are correlated to CDBC. Among laboratory results, increased white blood cell counting (mainly neutrophil), lymphocytopenia, increased procalcitonin, erythrocyte sedimentation rate, C-reaction protein, D-dimer, blood urea nitrogen, lactate dehydrogenase, brain natriuretic peptide, myoglobin, blood sugar and decreased albumin are also observed, indicating multiple system functional damage. Radiology results suggested ground glass opacity mixed with high density effusion opacities and even pleural effusion.

Conclusion: The aged COVID-19 patients with increased inflammatory indicators, worse lymphopenia and cardiovascular comorbidities are more likely to have clinically diagnosed bacterial co-infection. Moreover, they tend to have severer clinical manifestations and increased probability of multiple system functional damage.

Citing Articles

The significance of monitoring respiratory sample cultures and polymerase chain reaction tests for detecting bacterial pathogens in severely and critically ill patients with COVID-19.

Strelkova D, Kuleshov V, Burmistrova E, Sychev I, Savochkina Y, Danilov D Afr J Thorac Crit Care Med. 2024; 30(1):e1293.

PMID: 39544846 PMC: 11561391. DOI: 10.7196/AJTCCM.2024.v30i1.1293.


Are C-reactive protein and procalcitonin safe and useful for antimicrobial stewardship purposes in patients with COVID-19? A scoping review.

Williams A, Repetto E, Lebbie I, Khalife M, Jensen T Antimicrob Steward Healthc Epidemiol. 2024; 4(1):e129.

PMID: 39290622 PMC: 11406566. DOI: 10.1017/ash.2024.372.


Outbreak of colistin and carbapenem-resistant Klebsiella pneumoniae ST16 co-producing NDM-1 and OXA-48 isolates in an Iranian hospital.

Sanikhani R, Akbari M, Hosseinzadeh M, Siavash M, Badmasti F, Solgi H BMC Microbiol. 2024; 24(1):59.

PMID: 38368365 PMC: 10874040. DOI: 10.1186/s12866-024-03207-6.


Use of nares swab to de-escalate vancomycin for patients with suspected methicillin-resistant .

Gentges J, El-Kouri N, Rahman T, Mushtaq N, Hudson E, Scheck D Antimicrob Steward Healthc Epidemiol. 2023; 3(1):e167.

PMID: 38028911 PMC: 10644157. DOI: 10.1017/ash.2023.444.


Extended-spectrum β-lactamase- producing gram-negative bacterial infections in severely ill COVID-19 patients admitted in a national referral hospital, Kenya.

Mutua J, Njeru J, Musyoki A Ann Clin Microbiol Antimicrob. 2023; 22(1):91.

PMID: 37838665 PMC: 10576885. DOI: 10.1186/s12941-023-00641-8.


References
1.
Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J . Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015; 313(7):677-86. DOI: 10.1001/jama.2015.88. View

2.
Tsang K, Zhong N . SARS: pharmacotherapy. Respirology. 2004; 8 Suppl:S25-30. DOI: 10.1046/j.1440-1843.2003.00525.x. View

3.
Townsend L, Hughes G, Kerr C, Kelly M, OConnor R, Sweeney E . Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection. JAC Antimicrob Resist. 2020; 2(3):dlaa071. PMC: 7446659. DOI: 10.1093/jacamr/dlaa071. View

4.
Metlay J, Waterer G, Long A, Anzueto A, Brozek J, Crothers K . Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200(7):e45-e67. PMC: 6812437. DOI: 10.1164/rccm.201908-1581ST. View

5.
Lai C, Wang C, Hsueh P . Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?. J Microbiol Immunol Infect. 2020; 53(4):505-512. PMC: 7245213. DOI: 10.1016/j.jmii.2020.05.013. View